Quote | Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)
Last: | $9.45 |
---|---|
Change Percent: | -0.49% |
Open: | $10.3 |
Close: | $9.45 |
High: | $10.38 |
Low: | $9.31 |
Volume: | 2,917,035 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
News | Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)
2024-04-10 08:16:17 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture Arcutis announces pricing of $150 million public offering Arcutis lice...
WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper has been appointed Chief Financial Officer (CFO) effe...
Message Board Posts | Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Arcutis Biotherapeutics Inc. Company Name:
ARQT Stock Symbol:
NASDAQ Market:
WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage company focused on...
WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper has been appointed Chief Financial Officer (CFO) effe...
NESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved lar...